ClinicalTrials.gg
CompletedNCT04385095Updated Jan 4, 2023

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

A Phase 2 interventional study of SNG001 and Placebo in SARS-CoV-2, sponsored by Synairgen Research Ltd.. Completed at 13 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by Synairgen Research Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Interferon beta-1a in COVID-19 — 1 open to participants now, 1 under way, 1 of them phase 3. Interferon beta-1a · COVID-19.

Enrollment
7th of 12
221 · median 422
Started
2020
with 7 others
Phase 2
4 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
2 of 12
Synairgen Research Ltd.

Among the 12 studies testing Interferon beta-1a in COVID-19, this one is the 7th largest by enrollment, is one of 8 that started in 2020, is one of 4 in phase 2, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 12 studies testing Interferon beta-1a in COVID-19 is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Interferon beta-1a in COVID-19, or all of them as a file.
02

Study summary

SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-β). IFN-β in produced in the lungs during viral lung infections. It has been shown that older people and people with some chronic diseases have an IFN-β deficiency. Many viruses inhibit IFN-β as part of their strategy to evade the immune system.

Addition of IFN-β in vitro protects lung cells from viral infection. IFN-β protects cells against the MERS and SARS coronaviruses (close relatives of SARS-CoV-2, the virus that causes COVID-19).

SNG001 is an inhaled formulation of interferon beta-1a it is currently in Phase II clinical trials for COPD patients.

Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has:

  • been well tolerated during virus infections
  • enhanced antiviral activity in the lungs (measured in sputum and blood samples)
  • provided significant lung function benefit over placebo in asthma in two Phase II trials.

Synairgen believes SNG001 could help prevent worsening or accelerate recovery of severe lower respiratory tract illness in COVID-19 patients.

Patients who are in hospital or non-hospitalised but are a high risk groups (e.g. elderly or diabetics) will be invited to take part in the trial. The patient would receive either SNG001 or placebo once daily for 14 days. The severity of the patients condition would be recorded on a scale developed by the World Health Organisation and the patient would be asked questions about their breathlessness, cough and sputum every day, as well as assess their general medical condition and safety.

The study will start as a Pilot phase where 100 patients will be randomised in the hospital setting and a 120 patients randomised in the home setting.

Once each of the Pilot phases are complete, a Pivotal phase will be conducted. It is estimated that the size of each of the Pivotal phases (hospital and home) will be around 100 to 300 patients per arm. The actual number will be determined after the data review at the end of each of the Pilot phases.

If SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A. Hospital setting: positive virus test for SARS-CoV-2 using RT-PCR, or positive point-of-care viral infection test in the presence of strong clinical suspicion of SARS-CoV-2 infection.

    B. Home setting: positive virus test for SARS-CoV-2 using a molecular assay e.g. RT-PCR in the presence of strong clinical suspicion of SARS-CoV-2 infection.

  2. Male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent.
  3. A. Hospital setting: patients admitted to hospital due to the severity of their COVID 19 disease OR

    B. Home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors:

    • Arterial hypertension
    • Cardiovascular disease
    • Diabetes mellitus
    • Chronic lung disease
    • Chronic kidney disease ( \<60 mL/min/1.73m2)
    • Chronic liver disease
    • Immunodeficiency due to a serious illness or medication
    • Cerebrovascular disease
    • (except basal cell carcinoma) diagnosed in the last 5 years
    • ≥30 who present with clinical symptoms consistent with COVID-19:
    • High temperature and/or
    • New, continuous cough.
    • Loss or change to sense of smell and/or taste
  4. Provide .
  5. A. Hospital setting: hospitalised female patients must be ≥1 year , surgically sterile, or using an acceptable method of .

B. Home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.

Exclusion criteria

Exclusion Criteria:

  1. > 24 hours after confirmation of SARS-CoV-2 infection by a molecular assay e.g. RT-PCR test (hospital and home settings) or >24 hours after a positive point-of-care viral infection test (hospital setting only). This criterion does not apply to patients in the hospital setting who had their positive RT-PCR test for SARS-CoV-2 performed prior to hospitalisation.
  2. ≥ 8 days from onset of COVID-19 symptoms (cough and/or fever and/or loss or change to sense of smell and/or taste; home setting only).
  3. Any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation.
  4. Current or previous participation in another clinical trial where the patient has received a dose of an Medicinal Product (IMP) containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.
  5. Ventilated or in intensive care.
  6. Inability to use a nebuliser with a mouthpiece.
  7. History of to natural or recombinant IFN-β or to any of the in the drug preparation.
  8. Females who are breast-feeding, lactating, pregnant or intending to become pregnant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
221 participants (actual)

Study arms

  • Active comparator
    SNG001

    inhalation using the I-neb device.

    Drug: SNG001

  • Placebo comparator
    Placebo

    inhalation using the I-neb device.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Ordinal Scale for Clinical Improvement

    Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period - minimum of 0 (patient is well) to a maximum of 8 (death)

    Time frame: Day 1 to Days 15 and 28

Secondary outcomes

  1. Progression to pneumonia (hospital setting only)

    Progression to pneumonia as diagnosed by chest x-ray, if no pneumonia is present at time of enrolment

    Time frame: Day 2 to Day 28

  2. Progression to pneumonia (hospital setting only)

    Evolution of pneumonia, as diagnosed by chest x-ray, if pneumonia is present at time of enrolment

    Time frame: Day 1 to Day 28

  3. Time to clinical improvement (hospital setting only)

    Time to clinical improvement

    Time frame: Time to hospital discharge OR Time to NEWS2 of ≤ 2 maintained for 24 hours

  4. National Early Warning Score 2 (NEWS2) assessment of acute-illness severity (hospital setting only)

    NEWS2 assessment of acute-illness severity on a scale of 0 ( being well) up to 24 (requiring emergency response)

    Time frame: Day 1 to Day 28

  5. Changes in daily breathlessness, cough and sputum scale (BCSS)

    Changes in daily breathlessness, cough and sputum scale (BCSS) on a scale of 0 (no symptoms) up to 4 (severe symptoms)

    Time frame: Day 1 to Day 28 (and Day 60 and 90 home setting only)

  6. Safety and tolerability - blood pressure (hospital setting only)

    Looking at blood pressure measured in mmHg

    Time frame: Day 1 to Day 15

  7. Safety and tolerability - heart rate

    Looking at heart rate measured in beats per minute

    Time frame: Day 1 to Day 15

  8. Safety and tolerability - temperature

    Looking at temperature measured in degrees Celsius

    Time frame: Day 1 to Day 15

  9. Safety and tolerability - respiratory rate (hospital setting only)

    Looking at respiratory rate measure in breaths per minute

    Time frame: Day 1 to Day 15

  10. Safety and tolerability - oxygen saturation

    Looking at oxygen levels measured in a %

    Time frame: Day 1 to Day 15

  11. Safety and tolerability - adverse events

    Looking at adverse events (numbers and terms)

    Time frame: Day 1 to Day 28

  12. Safety and tolerability - concomitant medications

    Looking at concomitant medications given during treatment

    Time frame: Day 1 to Day 28

  13. Time to clinical improvement (home setting only)

    Temperature ≤37.8 °C AND COVID-19 symptoms (breathing, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and taste, rhinorrhoea and anorexia) all rated as absent or mild

    Time frame: Day 1 to Day 15

  14. Time to improvement of COVID-19 symptoms (home setting only).

    Time to improvement of COVID-19 symptoms (fever, breathing, cough, sputum, muscle aches, headache, fatigue, sore throat, loss or change to sense of smell and/or taste, rhinorrhoea and anorexia)

    Time frame: Day 1 to Day 28 and Day 60 and 90

  15. Time to self-reported recovery (home setting only)

    Time to self-reported recover

    Time frame: Day 2 to Day 15 and Day 28, 60 and 90

  16. Self-reported daily rating of overall feeling of wellness (home setting only).

    Self-reported daily rating of overall feeling of wellness scale from 1 (the worst you can imagine) to 10 (the best you can imagine)

    Time frame: Day 1 to Day 28 and Day 60 and 90

  17. Quality of life measured using EQ-5D-5L (home setting only).

    Quality of life measured using EQ-5D-5L - 5 questions where minimum score is 1 (best outcome) to 5 (worst outcome), visual analogue scale is also included for this 100 is best health you can imagine to 0 worst health you can imagine

    Time frame: Day 1 to Day 28 and Day 60 and 90

  18. Virus clearance/load (if samples are available)

    Time to virus clearance and viral load

    Time frame: Day 1 to Day 28

  19. Blood and sputum biomarkers (if samples are available).

    Blood and sputum biomarkers

    Time frame: Day 1 to Day 28

  20. Contact with health services (home setting only)

    Contact with health services

    Time frame: Day 1 to Day 28

  21. Consumption of antibiotics (home setting only)

    Consumption of antibiotics

    Time frame: Day 1 to Day 28

  22. General Anxiety Disorder 7 (home setting only)

    Assessment of anxiety - score of 0 (best) to 3 (worst)

    Time frame: Day 60 and 90

  23. Patient Health Questionnaire - 9

    Assessment of mental health - score of 0 (best) to 3 (worst)

    Time frame: Day 60 and 90

  24. FACIT Fatigue Scale

    Assessment of Fatigue - score of 0 (best) to 4 (worst)

    Time frame: Day 60 and 90

  25. Nottingham Extended Activities of Daily Living Scale

    Assessment of activities of daily living - no score just tick the box that applies; 'Not at all', 'With help', 'On your own with difficulty' and 'On your own'

    Time frame: Day 60 and 90

07

Study locations

13 sites
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Queen Elizabeth Hospital,
    Birmingham, B15 2GW, United Kingdom
  • Bradford Royal Infirmary
    Bradford, BD9 6RJ, United Kingdom
  • Park and St Francis Surgery
    Chandler's Ford, SO53 4ST, United Kingdom
  • Hull and East Yorkshire NHS Trust, Castle Hill Hospital,
    Hull, HU16 5JQ, United Kingdom
  • Glenfield Hospital,
    Leicester, LE3 9QP, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
  • City Campus of Nottingham University
    Nottingham, NG5 1PB, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
  • The Adam Practice
    Poole, BH15 2HX, United Kingdom
  • The Virtual Team
    Southampton, SO16 6YD, United Kingdom
  • University Hospital Southampton Nhs Foundation Trust
    Southampton, SO16 6YD, United Kingdom
  • Oaks Healthcare
    Waterlooville, PO8 8DL, United Kingdom
08

References and documents

Publications

  • Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA; Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12. PubMed 33189161 ↗
  • Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020 Oct;20(10):585-586. doi: 10.1038/s41577-020-00429-3. PubMed 32788708 ↗

Individual participant data

Plan to share: No — No plan to share data

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Feb 2021, 11 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
May 12, 2020
StartActual
Mar 16, 2020
Primary completionActual
Feb 17, 2021
CompletionActual
Nov 16, 2021
Last update
Jan 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04385095
Lead sponsor
Synairgen Research Ltd.
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Mar 16, 2020
Primary completion
Feb 17, 2021
Completion
Nov 16, 2021
Last update
Jan 4, 2023

Study contacts

Tom Wilkinson
principal investigator · Study Chief Investigator
Nick Francis
principal investigator · Study Deputy Chief Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interferon beta-1a · Interferon Beta-1a Inhalation Solution SNG001

Start the discussion